In this paper, we use time‐lapse, live‐cell imaging, and single‐cell analysis to show that BRAF‐mutant melanoma cells exhibit time‐variable and heterogeneous phenotypes when exposed to MAPK pathway inhibitors such as vemurafenib, dabrafenib, and trametinib near the IC50 for cell killing. Here, BRAF is linked to melanoma.